 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || live attenuated varicella vaccine / Sinovac
Trial completion date: An Immunity Persistence Study of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Jul 17, 2024
P4, N=703, Enrolling by invitation, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Trial completion date: Jul 2024 --> Dec 2024
- ||||| live attenuated varicella vaccine / Sinovac
New P4 trial: An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Jul 3, 2024
P4, N=414, Not yet recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- |||| live attenuated varicella vaccine / Sinovac
Enrollment open, Trial completion date: An Immunity Persistence Study of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Mar 12, 2024
P4, N=703, Enrolling by invitation, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Trial completion date: Jul 2024 --> Dec 2024 Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2022 --> Jul 2024
- |||||| live attenuated varicella vaccine / Sinovac
Enrollment open: Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ?13 Years Old (clinicaltrials.gov) - Mar 11, 2024
P3, N=2400, Enrolling by invitation, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2022 --> Jul 2024 Active, not recruiting --> Enrolling by invitation
- || live attenuated varicella vaccine / Sinovac
Clinical, Journal: Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 (Pubmed Central) - Jan 2, 2024
Active, not recruiting --> Enrolling by invitation VarV, manufactured by Sinovac (Dalian), demonstrated higher immune response and better flexibility in the immunization schedule among heathy population aged 13
- |||| live attenuated varicella vaccine / Sinovac
Enrollment open, Trial primary completion date: Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus (clinicaltrials.gov) - Jan 12, 2023
P4, N=37920, Recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
VarV, manufactured by Sinovac (Dalian), demonstrated higher immune response and better flexibility in the immunization schedule among heathy population aged 13 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2022 --> Mar 2023
- ||| live attenuated varicella vaccine / Sinovac
Enrollment closed: Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province (clinicaltrials.gov) - Jan 12, 2023
P4, N=45400, Active, not recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- || live attenuated varicella vaccine / Sinovac
P4 data, Journal: Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial. (Pubmed Central) - Jan 4, 2023
P4
The incidence rate of adverse reactions in Group A was lower than Group B (9.33% vs 16.22%), and only one serious adverse event was reported in Group B, which was unrelated to the study vaccine. In conclusion, the co-administration of VarV with HepA has non-inferior immunogenicity and safety profiles were quite comparable with the separate administration of both vaccines.Trial registration number: NCT05526820 (ClinicalTrials.gov).
- ||||| live attenuated varicella vaccine / Sinovac
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ?13 Years Old (clinicaltrials.gov) - Dec 9, 2022
P3, N=2400, Active, not recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
In conclusion, the co-administration of VarV with HepA has non-inferior immunogenicity and safety profiles were quite comparable with the separate administration of both vaccines.Trial registration number: NCT05526820 (ClinicalTrials.gov). Recruiting --> Active, not recruiting | Phase classification: P4 --> P3 | Trial completion date: Dec 2022 --> Sep 2026 | Trial primary completion date: Jul 2022 --> Feb 2022
- ||||| live attenuated varicella vaccine / Sinovac
New P4 trial: A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine (clinicaltrials.gov) - Sep 2, 2022
P4, N=450, Completed, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- ||||| live attenuated varicella vaccine / Sinovac
New P4 trial: Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province (clinicaltrials.gov) - Jul 23, 2022
P4, N=45400, Recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- ||||| live attenuated varicella vaccine / Sinovac
New P4 trial: Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus (clinicaltrials.gov) - Jul 15, 2022
P4, N=37920, Not yet recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- |||||||||| live attenuated varicella vaccine / Sinovac
New P3 trial: An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization (clinicaltrials.gov) - Dec 9, 2021
P3, N=1193, Completed, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- ||||| live attenuated varicella vaccine / Sinovac
New P4 trial: An Immunity Persistence Study of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Oct 26, 2021
P4, N=703, Not yet recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- |||| live attenuated varicella vaccine / Sinovac
Enrollment open: Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ?13 Years Old (clinicaltrials.gov) - Oct 15, 2021
P4, N=2400, Recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Recruiting --> Active, not recruiting | Phase classification: P4 --> P3 | Trial completion date: Dec 2022 --> Sep 2026 | Trial primary completion date: Jul 2022 --> Feb 2022 Not yet recruiting --> Recruiting
- ||||| live attenuated varicella vaccine / Sinovac
New P4 trial: Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ?13 Years Old (clinicaltrials.gov) - Aug 19, 2021
P4, N=2400, Not yet recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- |||||||||| live attenuated varicella vaccine / Sinovac
New P3 trial: A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Jul 15, 2018
P3, N=1197, Completed, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- ||||||| live attenuated varicella vaccine / Sinovac
Trial completion: A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines (clinicaltrials.gov) - Oct 26, 2017
P3, N=5997, Completed, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| live attenuated varicella vaccine / Sinovac
Trial completion: A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children (clinicaltrials.gov) - Oct 26, 2017
P1, N=270, Completed, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| live attenuated varicella vaccine / Sinovac
New P3 trial: A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines (clinicaltrials.gov) - Dec 4, 2016
P3, N=5997, Active, not recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.
- ||| live attenuated varicella vaccine / Sinovac
New P1 trial: A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children (clinicaltrials.gov) - Nov 16, 2016
P1, N=270, Active, not recruiting, Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.